Talk:Factor X deficiency
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
Some proposed changes
edit | This edit request by an editor with a conflict of interest was declined. Per: WP:V. |
This article needs the following statement corrected: “There are several treatments available for bleeding due to factor X deficiency, however a specific FX concentrate is not available (2009).” The reference for this statement is no longer up-to-date regarding current treatment options, and as of September 2018, COAGADEX® (Coagulation Factor X (Human)) is approved by the FDA for the treatment of adults and children with hereditary factor X deficiency. Please see The Genetic and Rare Diseases Information Center (GARD) website: https://rarediseases.info.nih.gov/diseases/6404/factor-x-deficiency
Kimwestclark (talk) 19:37, 13 February 2020 (UTC)
Reply 13-FEB-2020
edit
Clarification requested
- The text in question states that
"a specific FX concentrate is not available"
. The COI editor proposes that CoagaDex meets the definition of a specific FX concentrate. However, the reference supplied with the request does not state that this agent is an FX concentrate. Please provide references which use and verify the article's terminology.[a] - Meanwhile, until this clarification is provided, the article's statement about a specific concentrate not being available has been reworded to reinforce the claim that the statement was applicable as of 2009. That way, the statement is true even if there were later developments.
Regards, Spintendo 21:52, 13 February 2020 (UTC)
Notes
- ^ If the terminology used by the Wikipedia article is insufficient (such as, for example — in using the non-specific layman's term concentrate) then the COI editor is welcome to propose an alternative way of phrasing this information which may be more in line with the NIH reference already provided with their request.
Reply 27-FEB-2020
editThis response is to address the Clarification Request regarding the quote "a specific FX concentrate is not available"
, and the need for a reference which uses the article's terminology and describes Coagadex as an FX concentrate. Please see https://www.drugs.com/pro/coagadex.html, which addresses the approved indication for Coagadex, and specifically the section located at https://www.drugs.com/pro/coagadex.html#s-34089-3 which refers to Coagadex as a 'concentrate of human coagulation Factor X'.
Regards,